Merck to Present One-Year BRUNELLO Phase 2b/3 Results
Merck said it will present one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103) in adults with diabetic macular edema at AAO 2026.
Merck said it will present one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103) in adults with diabetic macular edema at AAO 2026.